Cybin (NYSEMKT: CYBN)
Cybin Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Cybin Company Info
Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Its goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.
News & Analysis
Why Cybin Stock Is Down on Monday
Positive pre-clinical data for CYB003 isn't nearly as exciting as investors hoped it would be.
These 4 Psychedelic Biotech Stocks Are Leading the Pack
Their clinical programs and research-enabling technologies both surpass the competition.
Buying Cybin Stock Right Now Could Be a Brilliant Move
You'll need to be prepared for a long holding period and a hearty helping of risk.
Missed the Initial Cannabis Boom? Check Out Hot Psychedelic Stock Cybin
The psychedelic-drug market is still in its early stages. And Cybin stands out as an early leader.
3 Reasons to Buy Cybin Stock, and 1 Reason to Sell
Several critical pieces are starting to fall into place for this clinical-stage biotech.
Could Cybin Be a Millionaire-Maker Stock?
The "new" mental health therapies this Canadian biotech is developing have an unusual advantage -- there's plenty of existing research showing that they work.
Forget Sundial Growers: Put This Psychedelic Stock on Your Radar
It's only in its early stages, but that could mean even bigger returns if the company's pipeline candidates are successful.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.